Coleman, R. L., Moon, J., Sood, A. K., Hu, W., Delmore, J. E., Bonebrake, A. J., . . . Markman, M. (2014). Randomized Phase II Study of Docetaxel Plus Vandetanib vs. Docetaxel Followed by Vandetanib in Patients with Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma: SWOG S0904.
Citación estilo ChicagoColeman, Robert L., James Moon, Anil K. Sood, Wei Hu, James E. Delmore, Albert J. Bonebrake, Garnet L. Anderson, Setsuko K. Chambers, and Maurie Markman. Randomized Phase II Study of Docetaxel Plus Vandetanib Vs. Docetaxel Followed By Vandetanib in Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma: SWOG S0904. 2014.
Cita MLAColeman, Robert L., et al. Randomized Phase II Study of Docetaxel Plus Vandetanib Vs. Docetaxel Followed By Vandetanib in Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma: SWOG S0904. 2014.